Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops

RECRUITING

I'm interested ...!!

Brief Summary: Nonimmune hydrops fetalis (NIHF) is a potentially fatal condition characterized by abnormal fluid accumulation in two or more fetal compartments. Numerous etiologies may lead to NIHF, and the underlying cause often remains unclear (1). The current standard of genetic diagnostic testing includes a fetal karyotype and chromosomal microarray (CMA), with an option to pursue single gene testing on amniocytes collected by amniocentesis (2). A large subgroup of the NIHF causes includes single gene disorders that are not diagnosed with the standard genetic workup for hydrops. Currently, nearly 1 in 5 cases of NIHF is defined as idiopathic, meaning there is no identified etiology (2). The investigators believe this is because the causes of NIHF are not completely investigated, specifically single gene disorders. Our research study aims to increase the diagnostic yield by performing whole exome sequencing (WES) and whole genome sequencing (WGS) on prenatal and neonatal NIHF cases when standard genetic testing is negative, identifying known and new genes, thus providing vital information to families regarding the specific diagnosis and risk to future pregnancies. The investigators plan to perform WES as the initial diagnostic test. If WES is negative, then the investigators will proceed to perform WGS.

Conditions:

🦠 Nonimmune Fetal Hydrops 🦠 Nonimmune Hydrops in Neonate 🦠 Genetic Disorders

🗓️ Study Start (Actual) 15 January 2019

🗓️ Primary Completion (Estimated) 30 June 2024

✅ Study Completion (Estimated) 31 December 2024

👥 Enrollment (Estimated) 55

🔬 Study Type OBSERVATIONAL

📊 Phase N/A

Locations:

📍 Philadelphia, Pennsylvania, United States

📋 Eligibility Criteria

Description

The following inclusion criteria will apply:
1. Fetal hydrops identified anytime in pregnancy after the first trimester
2. Parents are planning to proceed with amniocentesis as a routine workup for hydrops.
3. Both parents are available for blood sample collection
4. Normal CMA and normal karyotype if performed
5. Negative workup for Parvovirus B19, cytomegalovirus, toxoplasmosis, and syphilis
6. Negative fetomaternal hemorrhage workup as a cause for hydrops For cases of neonatal hydrops, the criteria for invasive prenatal testing will not be required as a postnatal blood sample from the hydropic infant will be the source of proband DNA.
The following exclusion criteria will apply:
1. Microarray was abnormal or karyotype was abnormal
2. Hydrops caused by congenital infection
3. Fetomaternal hemorrhage was a documented etiology for hydrops
4. Parental DNA cannot be obtained for either parents
5. Donor egg or donor sperm were utilized for conception
6. Fetus/Infant diagnosed with lysosomal storage disease
7. Pregnant woman or father of the baby less than 16 years of age
8. Hydrops was diagnosed concomitantly with intrauterine fetal demise

Ages Eligible for Study: 16 Years to 55 Years (CHILD, ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 9 April 2019
First Submitted that Met QC Criteria 9 April 2019
First Posted 11 April 2019

Study Record Updates